Some Analysts Just Cut Their Aster DM Healthcare Limited (NSE:ASTERDM) Estimates

One thing we could say about the analysts on Aster DM Healthcare Limited (NSE:ASTERDM) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the downgrade, the most recent consensus for Aster DM Healthcare from its six analysts is for revenues of ₹47b in 2026 which, if met, would be a solid 9.0% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing ₹57b of revenue in 2026. It looks like forecasts have become a fair bit less optimistic on Aster DM Healthcare, given the measurable cut to revenue estimates.

See our latest analysis for Aster DM Healthcare

There was no particular change to the consensus price target of ₹713, with Aster DM Healthcare's latest outlook seemingly not enough to result in a change of valuation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Aster DM Healthcare's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 19% growth to the end of 2026 on an annualised basis. That is well above its historical decline of 15% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 19% annually. So it looks like Aster DM Healthcare is expected to grow at about the same rate as the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for Aster DM Healthcare this year. They're also forecasting for revenues to grow at about the same rate as companies in the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Aster DM Healthcare going forwards.

Looking to learn more? We have estimates for Aster DM Healthcare from its six analysts out until 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.